Weak Q1, recovery unproven, NPA concentrated
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Missed prior ₹1,000–1,200 Cr quarterly disbursement target (delivered ₹117 Cr). Maintained NIM guidance (3.5–4.0%, delivered 4.46%). Asset quality stable but highly concentrated.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 revenue -27% YoY, PAT -70% YoY; major miss vs. ₹1,000–1,200 Cr quarterly disbursement aspiration (delivered ₹117 Cr). New MD cites transition and Q2 early signals (>₹1,200 Cr sanctions, record 13-quarter pace) support recovery narrative. However, execution track record is poor, NPA concentration (₹187 Cr of ₹190 Cr, 98.4% in one NCLT-pending account) is severe, and management hedged commitments. Wait for Q2 disbursement realization and NCLT progress.
₹103.3 Cr
Revenue · −27.2% YoY₹40.2 Cr
Reported PAT · −70.5% YoYFlat
Margins · vs guidance: OverstatedDid the claims hold up?
Disbursements ₹117 Cr reflect calibrated growth, portfolio consolidation
METDelivered 117 Cr vs. 1000–1200 Cr target; 90% miss attributed to project delays and leadership recalibration
NIM healthy at 4.46%, ROA 3.31%, RONW 5.19%
METNIM confirmed; but low ROA/RONW suggests high fixed costs relative to asset base
Momentum changed; Q2 sanctions >1,200 Cr in first month (record 13-quarter pace)
METConfirmed; however sanctions ≠ disbursal; execution depends on borrower construction milestones
Asset quality stable; Gross Stage III ~6.4% of loan assets, net 2% of NW
MISSTrue, but 98.4% of Stage III (₹187 Cr of ₹190 Cr) concentrated in ONE legacy account pending NCLT
Positioned for stronger growth trajectory going forward
OVERSTATEDTrack record poor (revenue -27%, PAT -70%); recovery unproven; depends on Q2-Q4 disbursement realization
Earnings quality
What changed since the last call
Leadership recalibration
NewNew MD Rajiv Malhotra took charge; prior MD departed. Cited reason for Q1 measured origination. Renewed focus on infrastructure financing, pause on FI/SME book.
Disbursement guidance reframed
DowngradePrior: ₹1,000–1,200 Cr quarterly run-rate. Now: ₹5,000 Cr AUM by FY27-end (implies ~1000–1200 Cr average). Q1 miss (₹117 Cr) signals lower near-term confidence vs. prior aspiration.
Cost of funds unresolved
MaintainedPrior calls flagged high borrowing cost. This call reaffirms; management chasing existing lenders, pursuing new facilities by end Q2. No structural solution yet.
NPA composition clarity
NeutralPrior implied ongoing broad NPA deterioration. This clarifies: ₹187 Cr (98.4%) of ₹190 Cr Stage III in ONE legacy account, NCLT-pending. Isolated.
The Q&A
Strong retail investor pushback throughout (Chana Mallu, Ranjap Singh). Challenged 3–4 year track record: revenue -27% YoY, PAT -70% YoY, no dividend, negative shareholder returns. Management defensive but held recovery narrative ('give us 2–3 quarters'). No institutional participation. No specific forward targets offered to satisfy skeptics.
Track record & value creation — Chana Mallu, individual investor
DodgedPast was not encouraging; management equipped to build value; stay invested, deliver next few quarters.
Future growth & dividend — Ranjap Singh, individual investor
PartialManagement committed to infrastructure investment & value creation; ask for patience 2–3 quarters; India story good for 10–20 years; dividend timing unclear.
Fundraising & cost of funds — Suyash Bhave, Wealth Guardian
AnsweredNo problem raising funds directionally. Cost is strategy priority; reducing progressively. New sanctions expected by end Q2 from multiple lenders.
Legacy NPA progress — Hukam Singhal, individual investor
AnsweredNCLT application pending admission; resolution process to commence once admitted, expected Q1 FY27.
Q1 disbursement miss — Hukam Singhal, individual investor
AnsweredInfrastructure financing phased; project delays in oil/gas (construction behind schedule); leadership recalibration also caused measured approach; Q2 >₹1,200 Cr sanctions already sanctioned.
Loan book trajectory — Hukam Singhal, individual investor
AnsweredExpect AUM to reach ₹5,000 crores by end of FY27. Yes, will increase.
NPA details & divestment — Ranjap Singh, individual investor
Partial₹187 Cr in NCLT account (of ₹190 Cr total Stage III). Divestment: defer to parent PTC's call.
Guidance
AUM ₹5,000 Cr by FY27-end (implies strong Q2-Q4 disbursal conversion)
MediumBased on >₹1,200 Cr Q2 sanctions and stated 'good pipeline.' Assumes 4–5 quarters of consistent sanction-to-disbursal conversion. No specific FY27 revenue/PAT target given.
NIM 3.5–4.0% (prior guidance, maintained)
HighQ1 delivered 4.46% (above range). Management confident on NIM sustainability via infrastructure lending focus and cost management.
Risks the call surfaced
NPA concentration
High₹187 Cr of ₹190 Cr Gross Stage III (98.4%) in ONE legacy account pending NCLT admission. If NCLT rejects or valuation low, significant loss potential.
Sanction-disbursal gap
HighQ2 >₹1,200 Cr sanctioned but not yet disbursed. Conversion depends on borrower construction milestones; oil/gas projects delayed due to commodity/geopolitical factors.
Cost of funds
MediumPrior management flagged cost of funds as headwind. New facilities not yet sanctioned (expected by end Q2). If cost remains high, margin pressure persists despite 4.46% NIM.
Execution track record
HighQ1 delivered ₹117 Cr vs. ₹1,000–1,200 Cr target (90% miss). Revenue -27% YoY, PAT -70% YoY. New MD (Rajiv Malhotra) on maiden call; credibility unproven. Asks for 'next 2–3 quarters' without specific milestones.
Balance-sheet shrinkage
MediumLoan assets ₹2,946 Cr; low Q1 disbursal (₹117 Cr) vs. likely repayments imply book contraction. AUM target ₹5,000 Cr by year-end requires 70% growth in 9 months.
Management
Score 6/10. New MD attempts confidence but hedges commitments. Acknowledged past failures transparently ('period not very encouraging'). Provided some operational detail (NPA breakdown, sanctions figures) but withheld specific FY27 revenue/PAT targets. Deflected dividend question ('cannot answer today'). Track record poor: Q1 ₹117 Cr disbursal vs. ₹1,000–1,200 Cr target (90% miss). Revenue -27% YoY, PAT -70% YoY. Early Q2 signals (>₹1,200 Cr sanctions, record 13-quarter pace) positive but unproven. Management requests '2–3 quarters' for proof.
1 · Sep 2026
Q2 disbursal realization from >₹1,200 Cr sanctions
2 · Sep 2026
NCLT admission & resolution process begin for ₹187 Cr legacy NPA
3 · Sep 2026
New lending facility sanctions expected from multiple institutions
Wait for Q2 disbursement realization and NCLT progress.
New MD, Unproven Recovery, Market Already Priced Out the Hope
Q1 revenue slumped 27%, profit fell 70%, and disbursement came in at just ₹117 Cr against a ₹1,000–1,200 Cr target. Management blames transition and claims Q2 recovery is already here. The street remains unconvinced.
₹103.3 Cr
-27.2% YoY
₹40.2 Cr
-70.5% YoY
4.46%
vs. 3.5–4.0% target
3.31% / 5.19%
low despite NIM strength
PTC India's Q1 looks like a study in misalignment. On the surface: revenue fell 27% year-on-year to ₹103.3 Cr, profit crashed 70% to ₹40.2 Cr. On the margin front: net interest margin held a strong 4.46%, above the 3.5–4.0% guidance band. The paradox is stark — the lending margin is healthy, but the lending book is shrinking faster than the company can grow it. That is the quarter.
The Q1 disbursement miss that started it all
In prior FY-2026 calls, management guided for a "significant acceleration" in Q4 FY'26, targeting ₹1,000–1,200 crore quarterly disbursements and ~15% sequential AUM growth. This quarter, actual disbursements came to ₹117 Cr — a 90% miss on the prior aspiration. The reason: a new MD took charge mid-quarter and decided to recalibrate. New MD Rajiv Malhotra inherited what he described on the call as a portfolio needing 'recalibration.' Infrastructure lending got refocused; the FI and SME books were put on pause. But the reset meant Q1 was always going to look weak.
What management is betting on now: Q2 is already here, and sanctions of >₹1,200 Cr have been approved — a record 13-quarter monthly pace. If those convert to disbursal in the coming weeks, the narrative flips. If they don't, it's proof that the prior MD wasn't wrong about the challenges, and the new MD inherited a book where the problem isn't strategy — it's execution.
Management claims vs. reality: what holds
Disbursements reflect calibrated portfolio consolidation
₹117 Cr vs. ₹1,000–1,200 Cr prior target (90% miss)
Supported by transition, but credibility depends on Q2 realization
NIM healthy at 4.46%, suggesting strong asset quality
NIM confirmed at 4.46%; but ROA 3.31%, RONW 5.19% are low, pointing to high fixed costs
Partially supported — NIM is real, but quality doesn't explain the low returns
Asset quality stable; NPA not a broad deterioration
Gross Stage III ₹190 Cr (6.4% of assets); ₹187 Cr (98.4%) in ONE legacy NCLT account
Supported — the bad news is isolated, not systemic
Q2 sanctions >₹1,200 Cr (record 13-quarter) signal momentum
Confirmed; but sanctions ≠ disbursals. Conversion depends on borrower capex milestones, project delays cited
Overstated on confidence — it's a leading indicator, not proof
Positioned for stronger growth trajectory going forward
Track record poor (revenue -27%, PAT -70%); recovery unproven; depends on Q2-Q4 execution by new MD
Contradicted — it's a hope, not a demonstrated trajectory
What changed on this call
Three material shifts:
Leadership transition, not announcement. New MD Rajiv Malhotra took charge mid-Q1. Prior MD exited (reason not disclosed). The reset created Q1 weakness and is now justifying the pivot to infrastructure focus and pause on FI/SME lending.
Disbursement guidance downgraded to AUM guidance. Prior call: ₹1,000–1,200 Cr quarterly disbursement run-rate. This call: ₹5,000 Cr AUM by FY27-end (implies ~1,000–1,200 Cr average over 9 months, a weaker commitment). The shift from a near-term metric to a year-end target signals lower confidence in near-term delivery.
NPA composition clarity: one account, not many. Prior calls implied ongoing broad NPA deterioration. This call isolates ₹187 Cr (98.4% of ₹190 Cr Gross Stage III) in ONE legacy account, NCLT-pending. Binary outcome, not tail risk.
The bull case vs. the bear case
NIM healthy (4.46%), above guidance; credit quality real
Infrastructure focus aligned with India's 10–20 year capex cycle
Q2 sanctions (>₹1,200 Cr) signal management conviction
NPA isolated to one legacy NCLT account (not systemic)
Strong capital base (₹3,120 Cr NW); excess capital available for growth
Revenue -27% YoY; PAT -70% YoY — volume collapse dominates
Disbursement miss (₹117 Cr vs. ₹1,000–1,200 Cr target) is 90% below aspiration
New MD unproven; asks for 2–3 quarters without specific milestones
Sanction-to-disbursal gap is real (project delays, borrower capex milestones)
Cost of funds unresolved; new lending facilities not yet sanctioned
Retail investor pushback on 3–4 year track record; no dividend visibility
Stock down 31% from ATH, RSI oversold (12.6), but day-1 -3.47% reaction held
Risks, ranked by how much they should concern a holder
NPA concentration: ₹187 Cr (98.4% of ₹190 Cr Gross Stage III) in ONE legacy NCLT-pending account
HighBinary outcome risk. If NCLT rejects admission or valuation is low, material loss to equity. The queue for NCLT resolution is long; timing uncertain. Resolved only post-admission process, expected Q1 FY27 (but no guarantee).
Sanction-to-disbursal gap: >₹1,200 Cr sanctioned in Q2 but not yet disbursed
HighConversion depends on borrower construction milestones. Oil/gas projects cited as delayed due to commodity/geopolitical factors. If >50% of Q2 sanctions fail to convert by Q3, recovery narrative collapses and new MD credibility takes a hit.
Execution track record: new MD unproven; prior MD also missed targets
HighThe entire bull case hinges on Q2-Q4 execution by a first-time caller (new MD). No track record to point to. Prior MD also claimed growth and underwhelmed. Street is wait-and-see; profit-taking if Q2 doesn't deliver.
Cost of funds: high borrowing cost vs. asset yields; new facility sanctions pending
MediumNIM 4.46% is solid, but margin sustainability depends on cost reduction. New facilities not yet sanctioned (expected end Q2). If cost doesn't improve, near-term ROA/RONW pressure persists despite AUM growth.
Balance-sheet shrinkage: loan assets ₹2,946 Cr (organic decline QoQ)
MediumLow Q1 disbursal (₹117 Cr) likely masked by repayments. AUM target of ₹5,000 Cr by FY27-end requires 70% growth in 9 months — aggressive and execution-dependent. If sanctions don't convert, book shrinkage continues.
Macro headwinds: oil/gas project construction delays; commodity/geopolitical cycle exposure
MediumPrimary loan book exposure is infrastructure (oil/gas, power, etc.). Delay in one sector delays loan conversion. No hedging or offset described.
How the street is positioned (and what the market's own verdict is)
Price action & drawdown. The stock closed the day before result announcement at ₹28.78. On day 1 post-result, it fell 3.47%; by day 3, it was down 3.93% cumulatively. The sell-off did not reverse, which is the street's own verdict: the weak numbers and reset narrative were expected. No relief rally happened, and the stock is now at ₹27.65, down 31.73% from its all-time high of ₹40.5. Below SMA20, SMA50, and SMA200 — the technical backdrop is bearish.
Valuation & opportunity context. RSI stands at 12.6 (oversold territory), suggesting the selloff may be near-term extreme. The 52-week range is ₹23.85–₹40.5; the current price is 15.93% off the low but still 31.73% below ATH. For a recovery narrative to work, the stock needs proof of Q2 execution, not just management intent.
Ownership & flows. FII holding stable at 2.13% (down 0.04pp QoQ), DII at 5.05% (down 0.01pp). Promoter holding flat at 64.99%. No large block trades reported. The lack of institutional buying into this weakness is telling — the recovery is priced in at the discount, but confidence is low. Retail investors on the call were vocal and skeptical ('multi-year zero capital return,' 'why stay invested'); management's response was defensive ('give us 2–3 quarters').
What to watch next
1 · Q2 disbursal realization from >₹1,200 Cr sanctions (Sep 2026)
The lynchpin. If >₹800 Cr (67%) converts to actual disbursal, recovery narrative survives. If <₹500 Cr, new MD's credibility is tested, and stock reprices lower. Watch for commentary on project delays in oil/gas, borrower construction timelines.
2 · NCLT admission & resolution process for ₹187 Cr legacy NPA (Sep 2026+)
Application is pending admission. Once admitted, the IBC process begins. Resolution timeline is 18–24 months typical, but equity recovery is uncertain. Update on timeline and recovery assumption will be key to Q2 call.
3 · New lending facility sanctions & cost of funds trajectory (end Q2)
Management flagged pending new facility sanctions from multiple lenders by end Q2. Cost reduction is critical to sustaining NIM and improving ROA/RONW. Watch for quantum of new facilities and cost reduction (bps) achieved.
4 · AUM progress toward ₹5,000 Cr by FY27-end (visibility by Dec 2026)
Target requires 70% growth from ₹2,946 Cr in 9 months (~₹280–300 Cr monthly average disbursal). By H2 call (Dec 2026), halfway to target should be visible. If on track, bull case gains traction. If lagging, turnaround timeline extends.
The honest read
This is not a step-change recovery story — it is an execution turnaround. Q1 was intentionally weak (new MD reset), and Q2 will test whether the reset was justified or a mistake. The bull case has merit (infrastructure is a real 10–20 year India tailwind, NPA is isolated, capital is strong), but the new MD has zero track record and zero credibility with the street. Management's ask for '2–3 quarters' is fair, but no patience remains — the stock has already repriced -31% from ATH.
The market's verdict is clear: 'Prove it in Q2.' RSI oversold (12.6) suggests near-term consolidation, but until disbursement realization is visible, institutional buying is unlikely. Retail investors on the call were burned by three years of poor returns and no dividend; they are skeptical, not hopeful.
The number to track from here is Q2 disbursal realization. If >₹800 Cr of the >₹1,200 Cr sanctions convert to actual disbursal, the turnaround is real, and the stock has room to re-rate. If <₹500 Cr, the problem is deeper than strategy, and the new MD will have to reset again. That binary is where the risk sits.
PTC Fin Services Q1FY27: PAT ₹40Cr, -71% YoY on high base; disbursements miss guidance
PAT -70.55% YoY · revenue -27.2% · margins expanding
₹103.31 Cr
-27.2% YoY
₹40.24 Cr
-70.55% YoY
38.95%
-57.1pp YoY
₹0.63
PTC India Financial Services (PFS) reported Q1 FY27 consolidated and standalone PAT of ₹40.24 Cr (identical on both bases, since the company's two associates contribute a nil profit/loss share after being fully impaired) — down 71% year-on-year from ₹136.63 Cr in Q1 FY26 and down 12% sequentially from ₹45.50 Cr in Q4 FY26. Revenue from operations was ₹103.31 Cr, down 27% YoY and 13% QoQ, the fourth consecutive quarter of topline contraction. The headline YoY profit collapse is however almost entirely a base effect: Q1 FY26 carried a ₹81.59 Cr impairment write-back (tied to the Rungta Mines settlement of the NSL Nagapatnam NPA and the ITPCL account's upgrade to standard) and a one-off ₹29.49 Cr tax credit (an earlier-year tax benefit linked to the ECEPL business-loss claim) — neither repeats this quarter, which has no exceptional items and only a routine ₹3.75 Cr impairment reversal. Adjusting for both one-offs, Q1 FY26's normalized PAT was closer to ₹47.4 Cr, making the real YoY profit decline about 15%, not 71%.
Q1 FY-2027 vs prior quarters
Margins actually held up better than the reported numbers suggest: net profit margin was 38.95% this quarter (per the company's own regulatory disclosure), roughly flat against Q4 FY26's 38.20% and, once Q1 FY26's one-offs are stripped out (normalized NPM of about 33%), an improvement YoY rather than the compression the raw 96%-to-39% comparison implies. Operating margin was 52.51%. The real weak spot is the top line: interest income keeps shrinking as the loan book stays undersized.
The stock went into the print at ₹28.78, down 8.3% over the past month of trading.
What the summary numbers don't show
Asset quality — Gross Stage 3 ratio 6.45%, Net Stage 3 ratio 1.68%, capital adequacy ratio 68.91%, net worth ₹3,120.12 Cr
Management guides for a significant acceleration in Q4 FY'26, targeting disbursements of INR 1,000-1,200 crores and a ~15% sequential AUM growth. Long-term strategy involves achieving a sustainable INR 1,000 crore quarterly disbursement run-rate by focusing on private sector lending and diversification into new infrast
— This quarter: missed
That topline weakness lines up with a clear miss against management's own guidance. On the Q3 FY26 call, management targeted a "significant acceleration" in Q4 FY26 disbursements to a ₹1,000-1,200 Cr run-rate and a long-term sustainable ₹1,000 Cr/quarter pace; the project-finance disclosure in this filing shows just 3 accounts sanctioned in Q1 FY27 worth ₹73.38 Cr, leaving the implementation book at only ₹309.93 Cr — an order of magnitude short of the guided run-rate. Management also flagged the final legacy NPA account for resolution by Q1 FY27; this filing's notes show no such resolution event (unlike Q1 FY26, which had two large recoveries), so that guidance checkpoint remains open. Governance adds uncertainty: the prior MD&CEO's resignation took effect June 30, 2026 (the last day of this quarter), and Rajiv Malhotra holds the role only in an additional-charge, interim capacity through November 30, 2026. Separately, PFS disclosed it breached the 75% minimum infrastructure-exposure threshold required for NBFC-IFC classification as of June 30, 2026, with remediation targeted for September 30, 2026 — consistent with a book that has been diversifying away from pure infra lending. No analyst consensus estimates for this print could be found (PFS has thin sell-side coverage), and no management press release or concall commentary on this specific quarter was available at extraction time, so beat/miss versus Street and management's own framing of the print remain unconfirmed pending the July 29, 2026 earnings call.
W1
Disbursement acceleration toward management's ₹1,000-1,200 Cr quarterly run-rate target — Q1 FY27 sanctioned just ₹73.38 Cr, so Q2 FY27 sanctions/AUM growth is the key checkpoint
W2
NBFC-IFC compliance restoration — infra exposure must reach 75% by September 30, 2026 (non-compliant as of June 30, 2026)
W3
Permanent MD&CEO appointment — Rajiv Malhotra's additional-charge term runs only through November 30, 2026